Eli Lilly (LLY) and Novo Nordisk (NVO) are competing heavily in the weight loss drug market. LLY's Zepbound recently beat NVO's Wegovy in a head-to-head trial, showing 20.2% weight loss versus 13.7%. NVO is trying to catch up with an oral version of Wegovy and new pipeline drugs, but LLY's pipeline looks stronger. LLY has its own oral drug launching soon that targets diabetes as well, plus a new drug in phase 3 trials that showed nearly 29% weight loss. Beyond obesity, LLY has a more diversified portfolio with treatments for cancer, Alzheimer's, and autoimmune conditions. NVO is mostly reliant on its GLP-1 lineup. Valuation is the main catch. LLY is trading at a steep 26.6x forward P/E compared to NVO at 10.9x. Even with the high price tag, LLY looks like the better overall buy right now because of its superior pipeline and broader product portfolio.